
Vaccine production (2016-17 to 2023-24) was highest for RDVK, peaking in 2021-22, while others like RDVF, DPV, and FPV fluctuated. Several vaccines, including HS Broth, Anthrax, and CSFV, had minimal or no output, showing a focus on key vaccines with irregular production for others.
